Insmed, Inc. (NASDAQ:INSM) headquartered in Bridgewater, will host a conference call for the investment community to discuss the 3Q20 financial results on 29th October 2020 at 8:30 AM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.insmed.com
Earnings Expectation
Insmed, Inc. is reporting third quarter financial results on Thursday 29th October 2020, before market open.
According to analysts surveyed by Thomson Reuters, INSM is expected to report 3Q20 loss of $ 0.61 per share from revenue of $ 46.07 million.
For the full year, analysts anticipate top line of $ 173.46 million, while looking forward to loss of $ 2.63 per share bottom line.
Insmed Incorporated, a global biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal.
